Clinical Trial Update: Study to Evaluate the Safety and Tolerability of PBI-4050 in Type 2 Diabetes Patients With Metabolic Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the safety and tolerability of PBI-4050 in patients with type 2 diabetes and metabolic syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Syndrome
• Type 2 Diabetes Mellitus

Drugs mentioned

• PBI-4050

Snippet

Sponsor: Liminal BioSciences Ltd. | Conditions: Type 2 Diabetes, Metabolic Syndrome | Phase 2 | Status: COMPLETED